The data shown below were collected from the profiles of 138 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia
|
|---|---|
| Published in |
European Journal of Clinical Microbiology & Infectious Diseases, February 2023
|
| DOI | 10.1007/s10096-023-04575-z |
| Pubmed ID | |
| Authors |
Zachary A. Yetmar, Ryan B. Khodadadi, John Raymond Go, Supavit Chesdachai, Omar M. Abu Saleh |
| Abstract |
Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia is associated with poor outcomes. Ceftriaxone offers logistical advantages over other standard therapies, though in vitro studies have questioned its efficacy and clinical studies of ceftriaxone in MSSA bacteremia are conflicting.We performed a multicenter, retrospective cohort study of adult patients who received ceftriaxone, cefazolin, or antistaphylococcal penicillins as definitive therapy for MSSA bacteremia from 2018 to 2019. Definitive therapy was defined as the antibiotic used in the outpatient setting. Patients were excluded if they received less than 7 days of outpatient therapy. Follow-up started on the date of definitive therapy completion. The primary outcome was 90-day treatment failure, defined as a composite of mortality and microbiologic recurrence. This was analyzed with multivariable Cox regression. A total of 223 patients were included, 37 (16.6%) of whom received ceftriaxone. The most common ceftriaxone dose was 2 g daily (83.8%). The most common primary site of infection was skin/soft tissue (37.2%), unknown (21.1%), and catheter-related (15.2%). Twenty-six (11.7%) developed infective endocarditis. Median total duration of treatment was 31.0 days, and median outpatient duration was 24.0 days. Twenty-six (11.7%) developed 90-day treatment failure. After adjusting for Charlson comorbidity index, duration of therapy, and use of transesophageal echocardiography, definitive treatment with ceftriaxone was associated with treatment failure (hazard ratio 2.66, 95% confidence interval 1.15-6.12; p=0.022). Among patients with MSSA bacteremia, definitive treatment with ceftriaxone was associated with a higher risk of treatment failure within 90 days as compared to cefazolin or antistaphylococcal penicillins. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 14 | 10% |
| United Kingdom | 3 | 2% |
| India | 2 | 1% |
| Mexico | 1 | <1% |
| Uganda | 1 | <1% |
| Colombia | 1 | <1% |
| Belgium | 1 | <1% |
| Japan | 1 | <1% |
| Pakistan | 1 | <1% |
| Other | 1 | <1% |
| Unknown | 112 | 81% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 110 | 80% |
| Practitioners (doctors, other healthcare professionals) | 16 | 12% |
| Scientists | 12 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 22% |
| Student > Bachelor | 2 | 9% |
| Researcher | 2 | 9% |
| Student > Ph. D. Student | 2 | 9% |
| Student > Postgraduate | 2 | 9% |
| Other | 3 | 13% |
| Unknown | 7 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 61% |
| Materials Science | 1 | 4% |
| Unspecified | 1 | 4% |
| Unknown | 7 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 93. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2024.
All research outputs
#482,961
of 26,330,421 outputs
Outputs from European Journal of Clinical Microbiology & Infectious Diseases
#19
of 3,170 outputs
Outputs of similar age
#11,209
of 435,290 outputs
Outputs of similar age from European Journal of Clinical Microbiology & Infectious Diseases
#1
of 35 outputs
Altmetric has tracked 26,330,421 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,170 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,290 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.